On Friday, the US Food and Drug Administration (FDA) approved as the first interchangeable biosimilar to Swiss pharma giant Roche's (ROG: SIX) anti-IgE monoclonal antibody Xolair (omalizumab).
The FDA granted the approval South Korea’s Celltrion (Kosdaq: 068270), which markets its biosimilar under the trade name Omlyclo.
Friday's US nod completes a global regulatory trifecta, following Omlyclo's authorization in the European Union in May 2024 and approval in Canada late last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze